A 26-year-old male with an intracranial teratoma, metastasizing from a testicular yolk sac tumor refractory to cis-diamminedichloroplatinum (CDDP), vinblastin, and bleomycin (PVB) therapy, was successfully treated with a combination of etoposide (VP-16), CDDP, and ACNU (salvage chemotherapy).
Introduction
Since the introduction of combined chemotherapy using cis-diamminedichloroplatinum (CDDP), vin blastin, and bleomycin (PVB therapy) for testicular tumors '41 long-term survival has been achieved in cases of intracranial malignant teratomas as well as gonadal germ cell tumors. However, not all cases achieved complete or partial remission and some relapses soon after treatment have occurred.
Here we discuss the complete remission of metastatic yolk sac tumor in the brain treated with etoposide (VP-16), CDDP, and ACNU, the so-called salvage chemotherapy. 
Case Report
A 26-year-old male had been treated for advanced testicular tumor in another hospital in January 1987.
Radiological examination identified right testicular tumor, multiple coin lesions in the lung (Fig. 1 A) , and lymphadenopathy in the para-aortic region. Serum alpha-fetoprotein was as high as 600 ng/ml. An or chiectomy was performed on January 6, 1987. The testicular tumor weighed 175 gm, and was diagnosed as yolk sac tumor (Fig. 2) . Postoperatively, he under went PVB therapy 3 times followed by CDDP, vinblastin, and cyclophosphamide once (Fig. 3 ). This chemotherapy was thought to have achieved complete remission based on the disappearance of all metastatic tumors on the chest x-ray film and normalization of the serum alpha fetoprotein level. A postcontrast computed tomographic (CT) scan showed no abnormal findings (Fig. 1B) and the neurological findings were normal.
He suddenly developed left hemiparesis and became comatose on August 5, 1987, and was admit ted to our hospital the next day. His consciousness level was 111-200 on the Japan Coma Scale and totally 7 on the Glasgow Coma Scale with left hemiplegia. A precontrast CT scan revealed sub cortical hemorrhage in the right frontal lobe (Fig.  4A ). Cerebral angiography showed no feeding arteries or tumor stain. A chest x-ray film demon strated no abnormal findings. HE stain, x 100. Fig. 3 Clinical course. Leukocytopenia is always followed by thrombocytopenia 1 or 2 days after ad ministration of VP-16 but recovers within a week.
PVB: combination chemotherapy of cis-diam minedichloroplatinum (CDDP), vinblastine, and bleomycin, PVE: combination chemotherapy of CDDP, vinblastine, and cyclophosphamide (Endoxan).
• : white blood cell (WBC), 0 : platelet (Pits), *: alpha-fetoprotein (AFP).
An emergency operation was performed for sub cortical hematoma removal and external decompres sion. The gross appearance was a mixture of glassy gray tissue within the hematoma. Histological exam ination revealed evidence of yolk sac tumor ( In October, however, a CT scan showed tumor recurrence ( Fig. 6A) On September 28, 1988, gallium scintigrams and a CT scan indicated tumor recurrence (Figs. 7 and 8A ), so the third operation was performed.
However, histological examination revealed only scar tissue. A third course of VP-16 was given from November 2, 1988, followed by intra-arterial administration of ACNU (176 mg) and CDDP (119 mg) on November 7, 1988. Further ACNU (125 mg) and CDDP (100 mg) were administered on May 9, 1989, and a fourth course of VP-16 (150 mg/day) was given from May 11. A follow-up CT scan demonstrated no evidence of tumor recurrence (Fig. 8B) .
He was doing well with no signs of tumor recur rence 30 months after the first operation. 
Discussion
Approximately 15% of malignant testicular tumors are thought to metastasize to the brain.'' Some tumors are refractory to PVB therapy or recur and cannot again be treated with the same chemo therapy. Therefore, a new therapeutic method is re quired for such refractory cases.
VP-16 was investigated many times in the late 1970s,9) and the results of phase II study using VP 16 for malignant testicular tumor were reported in 1985.1,11' These reports investigated recurrent cases previously treated with other chemotherapeutic drugs and since VP-16 was effective, it became an important drug in urology for refractory advanced testicular tumors as the so-called salvage chemo therapy.',",")
The mechanism of action of VP-16 in tumor cells is thought to be prevention of deoxy ribonucleic acid (DNA) synthesis in the S and G2 phases by means of single-strand breaks in DNA, which is cytotoxic to tumor cells. 15) It is adminis tered over 3-5 consecutive days in a total dose of 300-600 mg/m2, repeated every 3 or 4 weeks. As VP 16 is cell cycle specific and the half life is 3-7 hours, 3-5 fractions are more effective than a single dose.'' Maximum levels of the drug in the cerebrospinal fluid (CSF) are below 15% of the plasma level, showing the very poor water solubility of VP-16 limits the CSF presence.') Side effects with intravenous administration include alopecia in almost all cases and mild gastrointestinal toxicity. Laboratory analysis reveals myelosuppres sion in the majority of cases. Leukopenia and thrombocytopenia are more serious than anemia, with the former found in 70% of cases, and the latter in 30%.'' Leukocyte nadirs usually appear between the 11th and 19th days and thrombocyte nadirs between the 11th and 17th days from the beginning of intravenous drug administration. Recovery occurs by the 21st day.10' No serious complications occurred in some cases with triple the usual dosage (1500 mg) and no cumulative toxicity with repeated administration, but in others serious myelosuppression occurred with the usual dosage.'' Simultaneous use of both CDDP and VP-16 is effective against malignant tumor. Use of VP-16 only may be effective for advanced testicular tumor refrac tory to initial chemotherapy containing CDDP, but may not achieve complete remission .2,16' However, salvage chemotherapy combining VP-16 and CDDP achieved 41% complete remission and 30% long term survival in 80 cases. Pizzocaro et al. 10) treated 40 advanced testicular tumors with CDDP, VP-16, and bleomycin and surgical removal of residual tumors. This strategy achieved 82.5% complete remission with a mean survival of 24 months (13-40 months). They suggested the addition of VP-16 to the initial chemotherapy.
Gotoh et al .6) reported that salvage chemotherapy of CDDP and VP-16 given to four cases of ad vanced testicular tumor refractory to PVB therapy succeeded in complete remission in high dosage using 100 mg/m2 CDDP and 500 mg/m2 VP-16 in 5 doses, while low-dose therapy with 100 mg/m2 CDDP and 50 mg/m2 VP-16 failed to salvage in two cases. They advocated that high-dose salvage chemo therapy should be given immediately to patients with far advanced testicular tumor.
There are very few reports of VP-16 treatment of primary intracranial malignant germ cell tumor. Kobayashi et al.') reported four cases treated with CDDP and VP-16, observing tumor regression in all cases (three complete and one partial), a 100% response rate. Therefore, primary intracranial germ cell tumors may be effectively treated with low doses of VP-16 because of the synergic reaction of VP-16 and CDDP. However, as only a small amount of VP 16 enters the CSF, high-dose therapy will have a more complete effect on primary germ cell tumors.
We treated the present metastasis from the malig nant testicular tumor by a combination of intra arterial administration of 100 mg/m2 ACNU and 80 mg/m2 CDDP and intravenous administration of 500 mg/m2 VP-16. After the previous PVB therapy, the patient suffered sudden intracerebral hemorrhage containing malignant testicular tumor cells. Follow ing the first craniotomy, the metastatic lesion grew despite administration of CDDP (50 mg). The residual tumor, not totally removed at the second operation, disappeared after VP-16 therapy and was replaced by scar tissue found by the third operation. There was no tumor recurrence. These findings sug gest that salvage chemotherapy combining VP-16, CDDP, and ACNU has a remarkable effect on malig nant testicular tumor. In this case leukocytopenia was a significant side effect, but the leukocyte nadirs occurred 1 week after VP-16 administration, and recovered within a week every time. We could therefore be prepared to deal with this side effect by thrombocyte transfusion for the thrombocytopenia and the oral administration of antibiotics, antifungal drugs, and saline ultranebrizer containing antifungal drug for the leukocytopenia.
VP-16 has no cumulative toxicity and the clinical side effects can be dealt with adequately, so it can be given periodically and repeatedly for primary and metastatic malignant teratomas.
Addendum
The patient was still enjoying life without any signs of tumor recurrence in May, 1991. 
